Written by MarketBeatUpdated August 17, 2025 ShareLink copied to clipboard. Key Points Theravance Biopharma's stock reached a new 52-week high of $11.89 following a strong earnings report that showed an EPS of $1.08, significantly beating analysts' expectations of -$0.12. Analysts have mixed views on the stock, with Jones Trading upgrading it to a "strong-buy" with a price target of $24.00, while Wall Street Zen downgraded it from "buy" to "hold." Insider activity revealed that SVP Rhonda Farnum sold 24,000 shares for a total of $264,000, indicating a 6.65% decrease in her ownership, amidst broader insider sales totaling 44,000 shares over the past 90 days. Five stocks to consider instead of Theravance Biopharma. Like this article? Share it with a colleague. Link copied to clipboard. Featured Articles and OffersJoby Aviation's Pullback: A Gift for Investors Who See the FutureBy Jeffrey Neal Johnson | September 2, 2025What's the Best Way to Lower RMD Taxes?From SmartAsset (Ad)Lucid Group (NASDAQ:LCID) Stock Price Expected to Rise, Morgan Stanley Analyst SaysBy MarketBeat | September 6, 2025Jefferies Financial Group Issues Pessimistic Forecast for lululemon athletica (NASDAQ:LULU) Stock PriceBy MarketBeat | September 7, 2025Eyes on the Sky: AST SpaceMobile Prepares for Commercial LaunchBy Jordan Chussler | September 8, 2025Trump's Law S.1582: $21T Dollar Revolution ComingFrom Brownstone Research (Ad)Alphabet’s Resurgence: It's Now a Clear Market LeaderBy Ryan Hasson | September 2, 2025What to Watch for From D-Wave Now That Earnings Are DoneBy Nathan Reiff | September 2, 2025 Recent Videos Stock ListsAll Stock Lists5G Biotech Blue Chip FAANG Gold Large Cap Marijuana Micro Cap Oil REITs Russell 2000 Small Cap Warren Buffett Investing ToolsCalendars and ToolsAnalyst RatingsCryptocurrency ScreenerCongressional TradingDividend IncreasesDividend CalculatorDividend CalendarEarnings AnnouncementsInsider TradesOptions Profit CalculatorPenny StocksPortfolio MonitoringShort InterestStock ComparisonsStock Market HolidaysStock Screener Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Written by MarketBeatUpdated August 17, 2025 ShareLink copied to clipboard. Key Points Theravance Biopharma's stock reached a new 52-week high of $11.89 following a strong earnings report that showed an EPS of $1.08, significantly beating analysts' expectations of -$0.12. Analysts have mixed views on the stock, with Jones Trading upgrading it to a "strong-buy" with a price target of $24.00, while Wall Street Zen downgraded it from "buy" to "hold." Insider activity revealed that SVP Rhonda Farnum sold 24,000 shares for a total of $264,000, indicating a 6.65% decrease in her ownership, amidst broader insider sales totaling 44,000 shares over the past 90 days. Five stocks to consider instead of Theravance Biopharma. Like this article? Share it with a colleague. Link copied to clipboard.
